5 results
The current study is set up to validate the working mechanism of the current design of the FemFlow.
The overall goal of this RCT is to compare the efficacy of 90Y-RE to TACE-DEB, for patients with intermediate stage HCC. Time to progression, overall survival, tumor response, adverse events, treatment related effect on total liver function, quality…
The objective of this study is to confirm the safety and effectiveness of the Reducer when used in patients with refractory angina who demonstrate evidence of reversible ischemia.
Primary Objective: This study is set up to validate the patient comfort of the current design of the FemFlow. For the validation of the patient comfort, the FemFlow will be rated on:Comfort during insertion Comfort of an alien object in the bladder…
The objective of the study is to evaluate TheraSphere in the treatment of patients with unresectablehepatocellular carcinoma in whom treatment with standard-of-care sorafenib therapy is planned.